Correlation analysis on the expression levels of microRNA‑23a and microRNA‑23b and the incidence and prognosis of ovarian cancer
Open accessAbstract
The present study aimed to investigate the expression levels of microRNA (miR)-23a and miR-23b in the tumor tissues of patients with ovarian cancer. The study also explored the correlation of miR-23a and miR-23b expression levels in the tumor tissues with the clinic-pathological parameters and prognosis of the patients. Specimens of frozen tumor tissues and normal tissues adjacent to the tumor were collected from 50 patients with ovarian cancer. Reverse transcription-quantitative polymerase chain reaction was adopted to detect the expression levels of miR-23a and miR-23b in tumor tissues. Furthermore, normal tissues adjacent to the tumor were utilized as the control for the experiments and Pearson method was used to analyze the correlation between miR-23a and miR-23b expression levels in tumor tissues. The correlation of miR-23a and miR-23 expression in tumor tissues and the prognosis of the patients with ovarian cancer was analyzed in combination with clinical data. The expression of miR-23a in the tissues of ovarian cancer was significantly higher in comparison with normal adjacent tissues. However, the expression of miR-23b in the tissues of ovarian cancer was significantly lower when compared with adjacent normal tissues. Notably, the expression of miR-23a was negatively correlated with that of miR-23b in tumor tissues of ovarian cancer. The high expression of miR-23a and the low expression of miR-23b in tumor tissues of the patients was correlated with the degree of tumor differentiation, metastasis of lymph nodes and clinical staging. The five-year overall survival rate of the patients was 36% (18/50). Univariate survival analysis indicated that miR-23a and miR-23b were the factors influencing the overall survival rate of ovarian cancer. The present findings suggest that high expression of miR-23a and the low expression of miR-23b are closely correlated with the occurrence and development of ovarian cancer. The abnormal expression of the miR-23a and miR-23b could be utilized as potential prognostic molecular markers of ovarian cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
High expression of miR-23a and low expression of miR-23b both determine the occurrence and progression of ovarian cancer.
“the high expression of miR-23a and the low expression of miR-23b both determine the occurrence and progression of OC [86].”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [86]
The Results report higher miR-23a and lower miR-23b expression in ovarian tumors and associations with differentiation, lymph-node metastasis, and clinical stage. The Abstract says these expression patterns are ‘closely correlated’ with occurrence and development; it does not establish that they determine either one. Page numbers were not provided in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredIn tumor tissues of 50 ovarian cancer patients, expression levels of miR-23a/b were not identical in relation to clinical pathological parameters and prognosis, suggesting functional divergence among family members.
“in the tumor tissues of 50 patients with ovarian cancer (OC), researchers found that the expression levels of miR-23a/b were not identical in relation to the clinical pathological parameters and prognosis, suggesting there is a functional divergence among different family members.”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [86]
Expression of miR-23a is negatively correlated with expression of miR-23b in ovarian cancer.
“the expression of miR-23a is negatively correlated with the expression of miR-23b.”
From Recent advances of miR-23 in human diseases and growth development (2025) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
Yang, Z., Wang, X., Bai, R., Liu, W., Li, X., Liu, M., & Tang, H. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.244 · Cited by 49 · see citing works
Self-citationRetractedMicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068 · see citing works
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855 · see citing works
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499 · see citing works
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T. A., Chang, J. C. S., Markman, M. M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273 · see citing works
microPrimer: the biogenesis and function of microRNA
Du, T., & Zamore, P. D. (2005) · Development · doi:10.1242/dev.02070 · Cited by 809 · see citing works
On the road to reading the RNA-interference code
Siomi, H., & Siomi, M. C. (2009) · Nature · doi:10.1038/nature07754 · Cited by 674 · see citing works
AngiomiRs—Key regulators of angiogenesis
Wang, S., & Olson, E. N. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.04.002 · Cited by 448 · see citing works
MicroRNAs modulate the chemosensitivity of tumor cells
Blower, P. E., Chung, J.-H., Verducci, J. S., Lin, S., Park, J. K., Zunyan Dai, Y., Liu, C., Schmittgen, T. D., Reinhold, W. C., Croce, C. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0573 · Cited by 364 · see citing works
Huang, S., He, X., Ding, J., Liang, L., Zhao, Y., Zhang, Z., Xiao, Y., Pan, Z., Zhang, P., Li, J., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23580 · Cited by 204 · see citing works
Li, X., Liu, X., Xu, W., Zhou, P., Gao, P., Jiang, S., Lobie, P. E., & Zhu, T. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.478560 · Cited by 137 · see citing works
Optimal primary therapy of ovarian cancer
Bookman, M. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw088 · Cited by 99 · see citing works
Wen, Y., Lee, W.-J., Tan, P., Yang, S., Hsiao, M., Lee, L.-M., & Chien, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4229 · Cited by 81 · see citing works
MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression
Yan, J. Y., Jiang, J., Meng, X., Xiu, Y., & Zong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0307-1 · Cited by 73 · see citing works
MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease
Panera, N. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15079 · Cited by 60 · see citing works
Aghaee‐Bakhtiari, S. H., Arefian, E., Naderi, M., Noorbakhsh, F., Nodouzi, V., Asgari, M., Fard‐Esfahani, P., Mahdian, R., & Soleimani, M. (2015) · Tumor Biology · doi:10.1007/s13277-015-3057-3 · Cited by 50 · see citing works
Regulation of miR-23b expression and its dual role on ROS production and tumour development
Donadelli, M., Dando, I., Fiorini, C., & Palmieri, M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.012 · Cited by 47 · see citing works
Up-Regulation of Plasma miR-23b is Associated with Poor Prognosis of Gastric Cancer
Zhuang, K., Han, K., Tang, H., Yin, X., Zhang, J., Zhang, X., & Zhang, L. (2016) · Medical Science Monitor · doi:10.12659/msm.895428 · Cited by 32 · see citing works
The Role of miRNA in Haematological Malignancy
Gounaris-Shannon, S., & Chevassut, T. J. T. (2013) · Bone Marrow Research · doi:10.1155/2013/269107 · Cited by 28 · see citing works
Surgical management of recurrent ovarian cancer
Suh, D. H., Kim, H. S., Chang, S., & Bristow, R. E. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.537 · Cited by 26 · see citing works
Jin, A., Zhou, X., & Zhou, F.-Z. (2015) · PubMed · Cited by 6 · see citing works
Flagged first, then by citations
1 of the 23 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
microRNA-23a in Human Cancer: Its Roles, Mechanisms and Therapeutic Relevance
Wang, N., Tan, H., Feng, Y., Zhang, C., Chen, F., & Feng, Y. (2018) · Cancers · doi:10.3390/cancers11010007 · Cited by 101 · see citing works
Zhuang, R., Bai, X., & Liu, W. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1579960 · Cited by 45 · see citing works
Prahm, K. P., Høgdall, C. K., Karlsen, M. A., Christensen, I. J., Novotny, G. W., & Høgdall, E. V. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207319 · Cited by 42 · see citing works
Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs
Thomaidou, A. C., Batsaki, P., Adamaki, M., Goulielmaki, M., Baxevanis, C. N., Zoumpourlis, V. C., & Fortis, S. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158257 · Cited by 41 · see citing works
Small Non-Coding-RNA in Gynecological Malignancies
Dwivedi, S. K. D., Rao, G., Dey, A., Mukherjee, P., Wren, J. D., & Bhattacharya, R. (2021) · Cancers · doi:10.3390/cancers13051085 · Cited by 39 · see citing works
Ritter, A., Hirschfeld, M., Berner, K., Jaeger, M., Grundner-Culemann, F., Schlosser, P., Asberger, J., Weiß, D., Nöthling, C., Mayer, S., et al. (2020) · Cancer Biomarkers · doi:10.3233/cbm-190575 · Cited by 34 · see citing works
Ferreira, P., Roela, R. A., López, R. V. M., & Estevez-Diz, M. D. P. (2020) · Oncotarget · doi:10.18632/oncotarget.27246 · Cited by 34 · see citing works
Kaźmierczak, D., Jopek, K., Sterzyńska, K., Ginter-Matuszewska, B., Nowicki, M. O., Ruciński, M., & Januchowski, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072619 · Cited by 28 · see citing works
Jiang, T., Sun, L., Zhu, J., Li, N., Gu, H., Zhang, Y., Li, M., & Xu, J. (2022) · International Journal of Experimental Pathology · doi:10.1111/iep.12445 · Cited by 26 · see citing works
A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
Zhang, Y., Shi, X., Zhang, J., Chen, X., Zhang, P., Liu, A., & Zhu, T. (2021) · Scientific Reports · doi:10.1038/s41598-020-79694-0 · Cited by 23 · see citing works
Todeschini, P., Salviato, E., Romani, C., Raimondi, V., Ciccarese, F., Ferrari, F. G., Tognon, G., Marchini, S., D’Incalci, M., Zanotti, L., et al. (2021) · Cancers · doi:10.3390/cancers13133358 · Cited by 21 · see citing works
Wu, B., Xing, C., & Tao, J. (2019) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-019-1404-6 · Cited by 17 · see citing works
Fu, Y., & Sun, H. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-00979-1 · Cited by 14 · see citing works
Granulosa Cells-Related MicroRNAs in Ovarian Diseases: Mechanism, Facts and Perspectives
Xiao, S., Du, J., Yuan, G., Luo, X., & Song, L. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01523-w · Cited by 12 · see citing works
Park, N. R., Hoon, J., Sung, P. S., Jang, J. W., Choi, J. Y., Yoon, S. K., & Bae, S. H. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11135 · Cited by 11 · see citing works
Liu, J., Xu, F., Cheng, W., & Gao, L. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112235 · Cited by 9 · see citing works
The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer
Kozłowski, M., Borzyszkowska, D., Golara, A., Lubikowski, J., & Cymbaluk‐Płoska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073413 · Cited by 8 · see citing works
Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis
Parizadeh, S. M., Esfehani, R. J., Ghandehari, M., Hasanzadeh, M., Parizadeh, S. M. R., Hassanian, S. M., Kalat, A. R., Aghabozorgi, A. S., Rahimi-Kakhki, R., Zargaran, B., et al. (2019) · Current Drug Targets · doi:10.2174/1389450120666190708100308 · Cited by 8 · see citing works
Wadaa-Allah, A., Yahya, M., Elsaeidy, K. S., Alkanj, S., Hamam, K. M., El-Saady, M., & Ebada, M. A. (2020) · Meta Gene · doi:10.1016/j.mgene.2020.100651 · Cited by 7 · see citing works
Aldeli, N., & Hanano, A. (2025) · Reproductive Toxicology · doi:10.1016/j.reprotox.2025.108863 · Cited by 6 · see citing works
Recent advances of miR-23 in human diseases and growth development
Qian, X., Jiang, Y., Yang, Y., Zhang, Y., Xu, N., Xu, B., Pei, K., Yu, Z., & Wu, W. (2025) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.12.010 · Cited by 5 · see citing works
Soccio, P., Moriondo, G., Scioscia, G., Tondo, P., Bruno, G., Giordano, G., Sabato, R., Barbaro, M. P. F., Landriscina, M., & Lacedonia, D. (2024) · Non-coding RNA Research · doi:10.1016/j.ncrna.2024.09.008 · Cited by 4 · see citing works
Ranmale, S., Kumar, P., Tongaonkar, H. B., Mehta, S. S., Maniar, V., & Mania‐Pramanik, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1580565 · Cited by 3 · see citing works
DNA Damage and Repair in Ovarian Cancer: Focus on MicroRNAs
Arczewska, K. D., & Piekiełko‐Witkowska, A. (2025) · Cancers · doi:10.3390/cancers17183011 · Cited by 2 · see citing works
Moriondo, G., Soccio, P., Scioscia, G., Tondo, P., Bruno, G., Giordano, G., Sabato, R., Barbaro, M. P. F., Landriscina, M., & Lacedonia, D. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4579603 · Cited by 1 · see citing works
Kaźmierczak, D., Jopek, K., Sterzyńska, K., Ruciński, M., & Januchowski, R. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/859264
- Authors
- Su, L., & Liu, M.
- Affiliations
- Department of Obstetrics and Gynecology, Longnan Hospital, Heilongjiang 163001, P.R. China
- Daqing Oilfield General Hospital (CN)
- Corresponding author
- Liu, Mingmei
- ORCID
- Liu, Mingmei
- Venue
- Oncology Letters
- Publisher
- Spandidos Publications
- Published
- 2018-05-08
- Volume
- 16
- Issue
- 1
- Pages
- 262-266
- ISSN
- 1792-1074 (ISSN-L)
- 1792-1082
- PMC
- PMC6006491
- OpenAlex
- W2800083677
- Cited by
- 27
- References
- 23
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 2
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Oncology Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- ovarian cancer, microRNA-23a, prognostic factors, overall survival, tumor differentiation, lymph node metastasis, clinical staging, gene expression in tumor tissue
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
